at Nasdaq.com (Jan 23, 2015)
Shares of Theravance (THRX) soar over 18% in the post-trading session after coming off an...
Shares of Theravance (THRX) soar over 18% in the post-trading session after coming off an all-day trading halt while awaiting the FDA's decision on its COPD inhaler Breo Ellipta. The stock most recently traded at $33.25, after being halted earlier this morning at $28.01, as the FDA voted solidly in favor of approval.
How did this change your view of ?
More Bullish More Bearish It Didn't
This impact ()
Thanks for sharing your thoughts.
Submit & View Results
From other sites
Theravance Inc. (THRX): New Analyst Report from Zacks Equity Research - Zacks Equity Research Reportat Zacks.com (Jan 13, 2015)
at Zacks.com (Nov 10, 2014)
at CNBC.com (Jun 11, 2014)
at Fox Business (Feb 20, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs